Pure Global
NCT06328673

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

A First-in-Human Open-label, Phase 1a / 1b Dose Escalation and Expansion Cohort Study of DM919, a Novel Anti-MICA/B Antibody, as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
D2M Biotherapeutics Inc.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
DM919
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
D2M Biotherapeutics Inc.
Location
San Antonio, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Mar 01, 2024
End date
Mar 01, 2026
Enrollment
160 participants
Primary outcome

Number of treatment-emergent events (TEAEs) in Dose Escalation,RDEs or RP2Ds of DM919 alone and in combination with pembrolizumab

Summary

The goal of this clinical trial is to define a safe and effective dose of DM919 for
 participants with solid tumors
 
 The main questions it aims to answer are:
 
 What is the safe and effective dose of DM919 when used alone or in combination with
 pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination
 with pembrolizumab??
 
 Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or
 DM-919 in combination with pembrolizumab. They will have blood tests and other assessments to
 measure whether DM-919 will have the effect on tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06328673
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06328673 through Pure Global AI's free database. This Phase 1 trial is sponsored by D2M Biotherapeutics Inc. and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.